| 07.06. | CARA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) |  |
| 06.06. | Amarin Names Tom Reilly Finance Chief | |
| 06.06. | Cara Therapeutics CFO Thomas Reilly Resigns | |
| 03.06. | CARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) | |
| 03.06. | Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Offic.. | |
| 17.05. | Cara Therapeutics to Present at Upcoming Investor Conferences | |
| 10.05. | TRANSCRIPT : Cara Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conferenc.. | |
| 09.05. | TRANSCRIPT : Cara Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022 | |
| 09.05. | CARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an.. | |
| 09.05. | CARA : Q1 Earnings Snapshot | |
| 09.05. | Earnings Flash (CARA) CARA THERAPEUTICS Posts Q1 Revenue $4.8M | |
| 09.05. | Cara Therapeutics Reports First Quarter 2022 Financial Results | |
| 09.05. | Cara Therapeutics Reports First Quarter 2022 Financial Results | |
| 09.05. | Cara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, .. | |
| 03.05. | Cara Therapeutics to Present at May Investor Conferences | |
| 02.05. | Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022 | |
| 29.04. | Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022 | |
| 28.04. | Cara Therapeutics Wins EC Marketing Authorization for Kapruvia to Treat Chronic Kidney .. | |
| 28.04. | VIFOR : le Kapruvia approuvé par la Commission européenne |  |
| 28.04. | Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruri.. | |
| 28.04. | Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces the Eur.. | |
| 05.04. | Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference | |
| 04.04. | Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA&tra.. | |
| 29.03. | Cara Therapeutics Announces Oral KORSUVA (difelikefalin) Improves Itch and Inflammatory.. | |
| 28.03. | Cara Therapeutics Says Phase 2 Data of Drug Candidate for Atopic Dermatitis-Related Pru.. | |
| 28.03. | Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Infla.. | |
| 28.03. | Cara Therapeutics, Inc Announces Oral KORSUVA™ (difelikefalin) Improves Itch and I.. | |
| 12.03. | CARA THERAPEUTICS : 2022 R&D Day Presentation | |
| 11.03. | CARA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for.. | |
| 11.03. | TRANSCRIPT : Cara Therapeutics, Inc. - Special Call | |
| 09.03. | Cara Therapeutics Announces Oral KORSUVA (difelikefalin) Data Selected for Late-Breakin.. | |
| 08.03. | Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-.. | |
| 02.03. | Cara Therapeutics Files for Up to $300 Million Mixed-Securities Shelf | |
| 02.03. | Cara Therapeutics Swings to Q4 Loss, Missing Estimates -- Shares Drop 6% After Hours | |
| 01.03. | CARA THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K | |
| 01.03. | TRANSCRIPT : Cara Therapeutics, Inc., Q4 2021 Earnings Call, Mar 01, 2022 | |
| 01.03. | CARA : Q4 Earnings Snapshot | |
| 01.03. | CARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an.. | |
| 01.03. | Cara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2.. | |
| 01.03. | Earnings Flash (CARA) CARA THERAPEUTICS Posts Q4 Revenue $821,000, vs. Street Est of $1.. | |
| 01.03. | Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results | |
| 01.03. | Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results | |
| 01.03. | Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December .. | |
| 28.02. | Vifor Pharma Drug Gets Backing from European Medicines Agency Committee | |
| 28.02. | VFMCRP - Kapruvia receives positive CHMP opinion for the treatment of moderate-to-sever.. | |
| 28.02. | BOURSE ZURICH : le SMI ancré dans le rouge, après les sanctions contre la Russie | |
| 28.02. | BOURSE ZURICH : ouverture dans le rouge, sous le signe du conflit russo-ukrainien | |
| 28.02. | BOURSE ZURICH : la guerre en Ukraine continue de faire trembler les marchés | |
| 28.02. | VIFOR : recommandation européenne pour l'homologation du Kapruvia | |
| 25.02. | Cara Therapeutics, Vifor Say EMA Panel Backs Approval of Kapruvia for Itchy Skin in Hem.. | |
| 25.02. | Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe prurit.. | |
| 25.02. | Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announce CHMP Rec.. | |
| 22.02. | Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Ma.. | |
| 21.02. | Cara Therapeutics to Host Virtual R&D Day on March 11, 2022 | |
| 18.02. | Cara Therapeutics to Host Virtual R&D Day on March 11, 2022 | |
| 11.01. | Cara Therapeutics Announces Difelikefalin (KORSUVA) Injection Achieves Positive Topline.. | |
| 10.01. | TRANSCRIPT : Cara Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conferenc.. | |
| 10.01. | Cara Therapeutics Says Late-Stage Trial in Japan of Pruritus Treatment Meets Clinical E.. | |
| 10.01. | Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive .. | |
| 10.01. | Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive T.. | |
| 10.01. | CARA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Dis.. | |
| 03.01. | Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference | |
| 2021 | CARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) | |
| 2021 | Cara Therapeutics' Korsuva Injection Receives TDAPA Reimbursement | |
| 2021 | CARA THERAPEUTICS : Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection.. | |
| 2021 | CARA THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and.. | |
| 2021 | Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injectio.. | |
| 2021 | SWK Holdings Subsidiary Gets $5 Million Milestone Payment From Cara Therapeutics | |
| 2021 | Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confer.. | |
| 2021 | Cara Therapeutics to Present at Upcoming Investor Conferences | |
| 2021 | Cara Therapeutics Reports Narrower Q3 Loss | |
| 2021 | TRANSCRIPT : Cara Therapeutics, Inc., Q3 2021 Earnings Call, Nov 08, 2021 | |
| 2021 | Cara Therapeutics Reports Third Quarter 2021 Financial Results - Form 8-K | |
| 2021 | CARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an.. | |
| 2021 | CARA : Q3 Earnings Snapshot | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
